Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment of Advanced Non-small Cell Lung Cancer
Background and objective Pembrolizumab (PEM) has been shown to be effective in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC), but clinical trials were based on cohorts of patients selected on specific criteria, and whether the findings are consistent with real-worl...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2024-10-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2024.106.29 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850139179754717184 |
|---|---|
| author | Ning WAN Bing WANG Ya GUO Zijian HE Chen YANG Ning YANG Liqing LU Hongyi LIANG Weibin XIAO Dandan YANG Zhuojia CHEN Wenfeng FANG Weiting LIANG |
| author_facet | Ning WAN Bing WANG Ya GUO Zijian HE Chen YANG Ning YANG Liqing LU Hongyi LIANG Weibin XIAO Dandan YANG Zhuojia CHEN Wenfeng FANG Weiting LIANG |
| author_sort | Ning WAN |
| collection | DOAJ |
| description | Background and objective Pembrolizumab (PEM) has been shown to be effective in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC), but clinical trials were based on cohorts of patients selected on specific criteria, and whether the findings are consistent with real-world patients is debatable. The aim of this study is to evaluate the efficacy and safety of PEM in the treatment of advanced NSCLC based on real-world data. Methods A retrospective collection of real-world data from patients with advanced NSCLC receiving PEM was conducted. Propensity score matching was used to eliminate inter-group differences and assess the efficacy and safety of PEM compared to chemotherapy. Results Among 450 matched patients, the incidence rates of any-grade adverse events were 79.87% in the PEM group and 86.71% in the chemotherapy group, while the incidence rates of grade ≥3 adverse events were 4.03% and 7.31%, respectively. The objective response rates were 48.63% for PEM and 36.00% for chemotherapy (P=0.011). The median progression-free survival was 15.5 months for PEM and 8.8 months for chemotherapy (P<0.001), and the median overall survival was not reached for PEM and 26.2 months for chemotherapy (P<0.001). Conclusion PEM treatment for advanced NSCLC demonstrates favorable survival outcomes and acceptable safety in real-world clinical practice. |
| format | Article |
| id | doaj-art-f7e48e213b3349f69dc96ca4e441ba7e |
| institution | OA Journals |
| issn | 1009-3419 1999-6187 |
| language | zho |
| publishDate | 2024-10-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj-art-f7e48e213b3349f69dc96ca4e441ba7e2025-08-20T02:30:23ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872024-10-01271074575410.3779/j.issn.1009-3419.2024.106.29Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment
of Advanced Non-small Cell Lung CancerNing WAN0Bing WANG1Ya GUO2Zijian HE3Chen YANG4Ning YANG5Liqing LU6Hongyi LIANG7Weibin XIAO8Dandan YANG9Zhuojia CHEN10Wenfeng FANG11Weiting LIANG12Department of Clinical Pharmacy, General Hospital of Southern Theater Command, Guangzhou 510010, ChinaDepartment of Clinical Pharmacy, General Hospital of Southern Theater Command, Guangzhou 510010, ChinaDepartment of Clinical Pharmacy, General Hospital of Southern Theater Command, Guangzhou 510010, ChinaCollege of Pharmacy, Jinan University, Guangzhou 510623, ChinaDepartment of Clinical Pharmacy, General Hospital of Southern Theater Command, Guangzhou 510010, ChinaDepartment of Oncology, General Hospital of Southern Theater Command, Guangzhou 510010, ChinaDepartment of Clinical Pharmacy, General Hospital of Southern Theater Command, Guangzhou 510010, ChinaDepartment of Clinical Pharmacy, General Hospital of Southern Theater Command, Guangzhou 510010, ChinaDepartment of Clinical Pharmacy, General Hospital of Southern Theater Command, Guangzhou 510010, ChinaSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510120, ChinaDepartment of Pharmacy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, ChinaDepartment of Pharmacy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, ChinaBackground and objective Pembrolizumab (PEM) has been shown to be effective in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC), but clinical trials were based on cohorts of patients selected on specific criteria, and whether the findings are consistent with real-world patients is debatable. The aim of this study is to evaluate the efficacy and safety of PEM in the treatment of advanced NSCLC based on real-world data. Methods A retrospective collection of real-world data from patients with advanced NSCLC receiving PEM was conducted. Propensity score matching was used to eliminate inter-group differences and assess the efficacy and safety of PEM compared to chemotherapy. Results Among 450 matched patients, the incidence rates of any-grade adverse events were 79.87% in the PEM group and 86.71% in the chemotherapy group, while the incidence rates of grade ≥3 adverse events were 4.03% and 7.31%, respectively. The objective response rates were 48.63% for PEM and 36.00% for chemotherapy (P=0.011). The median progression-free survival was 15.5 months for PEM and 8.8 months for chemotherapy (P<0.001), and the median overall survival was not reached for PEM and 26.2 months for chemotherapy (P<0.001). Conclusion PEM treatment for advanced NSCLC demonstrates favorable survival outcomes and acceptable safety in real-world clinical practice.http://dx.doi.org/10.3779/j.issn.1009-3419.2024.106.29real-world datapembrolizumablung neoplasmssafetyefficacy |
| spellingShingle | Ning WAN Bing WANG Ya GUO Zijian HE Chen YANG Ning YANG Liqing LU Hongyi LIANG Weibin XIAO Dandan YANG Zhuojia CHEN Wenfeng FANG Weiting LIANG Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment of Advanced Non-small Cell Lung Cancer Chinese Journal of Lung Cancer real-world data pembrolizumab lung neoplasms safety efficacy |
| title | Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment
of Advanced Non-small Cell Lung Cancer |
| title_full | Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment
of Advanced Non-small Cell Lung Cancer |
| title_fullStr | Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment
of Advanced Non-small Cell Lung Cancer |
| title_full_unstemmed | Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment
of Advanced Non-small Cell Lung Cancer |
| title_short | Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment
of Advanced Non-small Cell Lung Cancer |
| title_sort | real world study of the safety and efficacy of pembrolizumab in the treatment
of advanced non small cell lung cancer |
| topic | real-world data pembrolizumab lung neoplasms safety efficacy |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2024.106.29 |
| work_keys_str_mv | AT ningwan realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT bingwang realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT yaguo realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT zijianhe realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT chenyang realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT ningyang realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT liqinglu realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT hongyiliang realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT weibinxiao realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT dandanyang realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT zhuojiachen realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT wenfengfang realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer AT weitingliang realworldstudyofthesafetyandefficacyofpembrolizumabinthetreatmentofadvancednonsmallcelllungcancer |